Morgan Stanley’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Morgan Stanley’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-751,051	Closed	-$15M	–	8163
2022 Q3	$15M	Buy	751,051 +40,992	+6%	+$541K	﹤0.01%	2519
2022 Q2	$4.89M	Buy	710,059 +194,819	+38%	+$1.37M	﹤0.01%	3792
2022 Q1	$4.79M	Buy	515,240 +344,746	+202%	+$3.67M	﹤0.01%	3737
2021 Q4	$2.42M	Sell	170,494 -11,854	-7%	-$205K	﹤0.01%	4422
2021 Q3	$4.23M	Buy	182,348 +73,886	+68%	+$1.75M	﹤0.01%	3912
2021 Q2	$2.7M	Buy	108,462 +5,833	+6%	+$157K	﹤0.01%	4391
2021 Q1	$2.88M	Buy	102,629 +17,570	+21%	+$634K	﹤0.01%	3967
2020 Q4	$2.97M	Buy	85,059 +81,682	+2,419%	+$3.56M	﹤0.01%	3807
2020 Q3	$168K	Buy	3,377 +3,353	+13,971%	+$136K	﹤0.01%	5198
2020 Q2	$1K	Buy	+24	New	+$1.04K	﹤0.01%	6553

Morgan Stanley's FMTX Position: Q4 2022 in Review

Morgan Stanley sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 751,051 shares — an estimated $15M sold.

Morgan Stanley first reported a position in FMTX in Q2 2020 and held it in 10 quarters. The position peaked at $15M in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Morgan Stanley reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Morgan Stanley sold 751,051 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $15M.
Morgan Stanley first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
Morgan Stanley's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $15M in Q3 2022.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.